Analysis of CD4+ T Cell Therapy for Advanced Ovarian Cancer followed Chemotherapy with PBSCT.

晚期卵巢癌化疗后 PBSCT 的 CD4 T 细胞治疗分析。

• 批准号: 13671742
• 负责人: MAEDA Hiroo
• 金额: $ 2.3万
• 依托单位: Saitama Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2001
• 资助国家: 日本
• 起止时间: 2001 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-13671742/
• 关键词: Ovarian cancer; T cell; IL-4; Cell therapy; 細胞治療

Peripheral blood stem cell transplantation (PBSCT) combined with chemotherapy for the patients with advanced ovarian cancer is an effective therapy but not a perfect one. Therefore, it is necessary to develop novel cell therapies followed this chemotherapy with PBSCT, in order to improve long term survival.At first we confirmed that the peripheral blood of the patients after anti-cancer chemotherapy possessed enough number of CD4 positive memory T cells. Next, we surveyed ovarian cancer-related antigen : CA125, to detect antigenic amino acid sequences in it. Among 48 of twenty amino acid residues analogue peptides, two kinds of sequences were able to activate CD4 positive T cells form the patients with ovarian cancer. In 25 samples of peripheral blood mononuclear cells, IL-4 and/or IFNγ were detected from 84% of the samples.From these results, it is possible to acquire cell therapeutic effects by CA125 analogue peptide-activated CD4 positive T cell for the patients followed chemotherapy with PBSCT.

外周血造血干细胞移植联合化疗治疗晚期卵巢癌是一种有效的治疗方法，但并不理想。因此，有必要在PBSCT化疗后开发新的细胞疗法，以提高患者的长期生存率。我们首先证实了抗癌化疗后患者的外周血中具有足够数量的CD 4阳性记忆T细胞。其次，我们对卵巢癌相关抗原CA 125进行了抗原性氨基酸序列的检测，在20个氨基酸残基的48个类似肽中，有两种序列能够激活卵巢癌患者的CD 4阳性T细胞。25例外周血单个核细胞中，IL-4和/或IFNγ的阳性率为84%，提示经CA 125类似肽激活的CD 4阳性T细胞对PBSCT化疗后患者有细胞治疗作用。

项目成果

Mitsuo Okubo, Maki Saito, Hiroki Inoku, Ranko Hirata, Masami Yanagisawa, Satoru Takeda, Katsuyuki Kinoshita, Hiroo Maeda.: "Analysis of HLA-DRB1^*0901-binding HPV-16 E7 Helper T cell Epitope."Journal of Obstetrics and Gynaecology Research. (In press). (20

Mitsuo Okubo、Maki Saito、Hiroki Inoku、Ranko Hirata、Masami Yanagisawa、Satoru Takeda、Katsuyuki Kinoshita、Hiroo Maeda.：“HLA-DRB1^*0901 结合 HPV-16 E7 辅助 T 细胞表位的分析。”妇产科杂志

Five-year results of cyclic semi-high dose chemotherapy supported by autologous peripheral blood stem cell transplantation in patients with advanced ovarian cancer.

自体外周血干细胞移植支持的周期性半高剂量化疗对晚期卵巢癌患者的五年结果。

• 发表时间: 2004
• 期刊: International Journal of Oncology 9
• 作者: Ikeba K;Okubo M;Takeda S;Kinoshita K;Maeda H.
• 通讯作者: Maeda H.

Five-Year Results of Cyclic Semi-high Dose Chemotherapy Supported by Autologous Peripheral Blood Stem Cell Transplantation in Patients with Advanced Ovarian Cancer

自体外周血干细胞移植支持的周期半高剂量化疗治疗晚期卵巢癌的五年结果

• 发表时间: 2004
• 期刊: International Journal of Clinical Oncology 9
• 作者: K Ikeba;M Okubo;S Takeda;K Kinoshita;H Maeda.
• 通讯作者: H Maeda.

Human papillomavirus type 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer

• DOI: 10.1002/ijc.11332
• 发表时间: 2003-10-10
• 期刊: INTERNATIONAL JOURNAL OF CANCER
• 影响因子: 6.4
• 作者: Matsumoto, K;Yasugi, T;Taketani, Y
• 通讯作者: Taketani, Y

Analysis of HLA-DRB1*0901-binding HPV-16 E7 helper T cell epitope.

HLA-DRB1*0901 结合 HPV-16 E7 辅助 T 细胞表位分析。

• 发表时间: 2004
• 期刊: J Obstet Gynaecol Res. 30
• 作者: 大久保光夫;前田平生;Okubo M. Saito M. Inoku H. Hirata R. Yanagisawa M. Takeda S. Kinoshita K. Maeda H.
• 通讯作者: Okubo M. Saito M. Inoku H. Hirata R. Yanagisawa M. Takeda S. Kinoshita K. Maeda H.